首页 > 用药指导 > 文章详情

Baricitinib(巴瑞替尼)艾乐明医保报销比例

发布时间:2023-12-19 12:57:58 阅读:1187 来源:问药网
分享至

分享到微信朋友圈

×

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

巴瑞替尼片

巴瑞替尼片 生产厂家:孟加拉碧康制药股份有限公司 功能主治:对一种或多种抗风湿药物缓解不足或不耐受的中度至重 用法用量:用法用量  1、类风湿性关节炎  OLUMIANT的推荐剂量为每日1次口服2mg,餐前餐后都可。  OLUMIANT可以单独使用,也可以与甲氨蝶呤或其他非生物dmard联合使用。  2、COVID-19(新冠病毒)  成人OLUMIANT的推荐剂量为每日一次口服4mg,餐前餐后都可,持续14天或直到出院,以先发生者为准。  3、斑秃  OLUMIANT的推荐剂量是2mg,每天一次口服,餐前餐后都可。  如果对治疗的反应不充分,增加到每天一次4mg。  对于几乎完全或完全的头皮脱发,睫毛或眉毛有或没有大量脱发的患者,考虑每天一次4mg治疗,伴餐前餐后都可。  一旦患者对4mg的治疗产生了充分的反应,将剂量减少到2mg,每天一次。  对于无法吞下整片药片的患者,可以考虑另一种给药方式:  1、口服分散  2、胃造口管(G管)  3、鼻胃管(NG管)或口胃管(OG管)
查看详情

Baricitinib(巴瑞替尼)艾乐明医保报销比例,Baricitinib(Baricitinib)已纳入医保报销。报销类别:医保乙类。各地区的相关政策不同,报销的比例也有所不同,一般在50%~70%之间。

Introduction:

Baricitinib (brand name Olumiant) is a medication used for the treatment of rheumatoid arthritis, COVID-19, and alopecia areata (also known as spot baldness). It is an oral medication that belongs to the class of drugs called Janus kinase (JAK) inhibitors. In this article, we will discuss the reimbursement coverage percentage for Baricitinib under medical insurance.

1. Reimbursement Coverage for Baricitinib:

The reimbursement coverage for Baricitinib may vary depending on the specific medical insurance plan and the country in which the individual resides. To obtain accurate information about the reimbursement coverage percentage for Baricitinib, it is best to consult with the relevant insurance provider or refer to the insurance policy.

2. Reimbursement Coverage for Baricitinib in the Treatment of Rheumatoid Arthritis:

Rheumatoid arthritis is a chronic autoimmune disease that causes inflammation in the joints. Baricitinib has been approved for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded well to other disease-modifying antirheumatic drugs (DMARDs). The reimbursement coverage for Baricitinib in the treatment of rheumatoid arthritis may depend on factors such as the severity of the disease, prior treatment history, and the specific insurance plan.

3. Reimbursement Coverage for Baricitinib in the Treatment of COVID-19:

During the COVID-19 pandemic, Baricitinib has been explored as a potential treatment for patients with severe symptoms caused by the SARS-CoV-2 virus. Clinical trials have shown that Baricitinib, in combination with other medications, can reduce the recovery time and progression to severe respiratory failure in hospitalized COVID-19 patients. The reimbursement coverage for Baricitinib in the treatment of COVID-19 may vary and is subject to the guidelines and policies of the respective medical insurance providers.

4. Reimbursement Coverage for Baricitinib in the Treatment of Alopecia Areata:

Alopecia areata is an autoimmune condition that causes hair loss, often in small patches on the scalp. Baricitinib has shown promising results in the treatment of alopecia areata, and clinical trials are still underway to determine its effectiveness in this regard. The reimbursement coverage for Baricitinib in the treatment of alopecia areata will depend on factors such as the extent of hair loss, treatment duration, and the specific insurance plan.

In conclusion, the reimbursement coverage percentage for Baricitinib under medical insurance is subject to various factors, including the specific indication for which it is prescribed, the severity of the condition, and the insurance provider's guidelines. To obtain accurate information about reimbursement coverage for Baricitinib, individuals should consult with their insurance provider and review their insurance policy to understand the terms and conditions associated with coverage for this medication.

孟加拉碧康制药股份有限公司碧康制药股份有限公司(Beacon,简称碧康制药)创建设于2001年,是孟加拉目前规模最大、技术最先进的抗肿瘤类和抗病毒类药物生产企业,也是该国成长最快的大型制药龙头企业。
直达企业主页

热门文章

更多